Nations Financial Group Inc. IA ADV Has $1.17 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Nations Financial Group Inc. IA ADV decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 64.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,998 shares of the company’s stock after selling 3,606 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Eli Lilly and Company were worth $1,165,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $26,000. Tidemark LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $29,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at $36,000. St. Johns Investment Management Company LLC lifted its holdings in Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the last quarter. Finally, O Brien Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 70.5% during the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.1 %

Shares of LLY stock traded down $1.02 during mid-day trading on Friday, reaching $807.43. 1,778,120 shares of the stock traded hands, compared to its average volume of 2,894,329. The stock’s fifty day simple moving average is $765.47 and its two-hundred day simple moving average is $692.97. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $820.60. The company has a market cap of $767.39 billion, a price-to-earnings ratio of 118.91, a price-to-earnings-growth ratio of 1.76 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period last year, the firm posted $1.62 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LLY. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Barclays increased their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.